Mediar Therapeutics
Founded 2018 · CIK 0001766784 · Biotech · Private
Small molecule therapeutics platform targeting novel fibrotic pathways for idiopathic pulmonary fibrosis (IPF)
mediartx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $75M
- 3 Form D · Dec 2025
- 10 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $31,761,186 | |
| Private capital raised | Form D · SEC | $37,849,815 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1262 | Young Biopharma, LLC | — | — |
| 1263 | Proteovant Therapeutics | — | — |
| 1264 | Pelthos Therapeutics Inc. | — | $69M |
| 1265 | Mediar Therapeutics | — | $75M |
| 1266 | MOLECULAR TECHNOLOGIES LABORATORIES LLC | — | — |
| 1267 | MARTINGALE LABS, INC. | — | — |
| 1268 | Monte Rosa Therapeutics, Inc. | — | $143M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Rahul BallalDirector · Executive Officer
- Michael BaranDirector
- Maina BhamanDirector
- Cassidy BlundellDirector
- Stacey BrennerExecutive Officer
- Adam CottonDirector
- David de GraafDirector
- Meredith FisherDirector · Executive Officer
- Brian HubbardDirector
- Andreas JurgeitDirector
- Anja KonigDirector
- Allan MarchingtonDirector
- Peter ParkerDirector
- Marie-Claire PeakmanDirector
- Nandita ShangariDirector
- Bharat SrinivasaDirector
- Simon SturgeDirector
Patents
- Anti-ephrin B2 Antibodies And Methods Of Useapplication
- ANTI-WISP1 Antibodies And Methods Of Useapplication
- Therapeutic Antibody Targeting WISP1 Proteinapplication
- Therapeutic Antibody Targeting WISP1 Proteinapplication
- Anti-ephrin B2 Antibodies And Methods Of Useapplication
- Therapeutic Antibody Targeting WISP1 Proteinapplication
- ANTI-WISP1 Antibodies And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.